Advanced search
Publication Cover
Therapeutic Delivery Volume 1, 2010 - Issue 6
Submit an article Journal homepage
227
Views
0
CrossRef citations to date
0
Altmetric
Review

Exploiting Nutrient Transporters at the blood–brain Barrier to Improve Brain Distribution of Small Molecules

Rajendar K Mittapalli1 Department of Pharmaceutical Sciences Texas Tech University Health Sciences Center School of PharmacyAmarilloTX79106–1712USA
,
Vamshi K Manda1 Department of Pharmaceutical Sciences Texas Tech University Health Sciences Center School of PharmacyAmarilloTX79106–1712USA
,
Chris E Adkins1 Department of Pharmaceutical Sciences Texas Tech University Health Sciences Center School of PharmacyAmarilloTX79106–1712USA
,
Werner J Geldenhuys2 Department of Pharmaceutical Sciences Northeastern Ohio Universities College of Pharmacy RootstownOH44272USA
&
Paul R Lockman1 Department of Pharmaceutical Sciences Texas Tech University Health Sciences Center School of PharmacyAmarilloTX79106–1712USA;3 [email protected]
Pages 775-784 | Published online: 03 Dec 2010

Bibliography

  • Pardridge WM . Drug targeting to the brain. Pharm. Res.24(9), 1733–1744 (2007).
  • Pardridge WM . Blood–brain barrier delivery. Drug Discov. Today12(1–2), 54–61 (2007).
  • Oku T , TjuvajevJG, MiyagawaTet al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 58(18), 4185–4192 (1998).
  • Neuwelt EA . Mechanisms of disease: the blood–brain barrier. Neurosurgery54(1), 131–142 (2004).
  • Smith QR . A review of blood–brain barrier transport techniques. Methods Mol. Med.89, 193–208 (2003).
  • Crone C , OlesenPS. Electrical resistance of brain microvascular endothelium. Brain Res.241(1), 49–55 (1982).
  • Nitta T , HataM, GotohSet al. Size-selective loosening of the blood–brain barrier in claudin-5-deficient mice. J. Cell Biol. 161(3), 653–660 (2003).
  • Kniesel U , WolburgH. Tight junctions of the blood–brain barrier. Cell. Mol. Neurobiol.20(1), 57–76 (2000).
  • Huber JD Egleton DR, Davis PT. Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier. Trends Neurosci.24(12), 719–725 (2001).
  • Rapoport SI . Osmotic opening of the blood–brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol.20(2), 217–230 (2000).
  • Howles GP , BingKF, QiY, RosenzweigSJ, NightingaleKR, JohnsonGA. Contrast-enhanced in vivo magnetic resonance microscopy of the mouse brain enabled by noninvasive opening of the blood–brain barrier with ultrasound. Magn. Reson. Med.64(4), 995-1004 (2010).
  • Minn A , Ghersi-EgeaJF, PerrinR, LeiningerB, SiestG. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res. Brain Res. Rev.16(1), 65–82 (1991).
  • Loscher W , PotschkaH, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol.76(1), 22–76 (2005).
  • Oldendorf WH . Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol.221(6), 1629–1639 (1971).
  • Tamai , I, Tsuji A. Transporter-mediated permeation of drugs across the blood–brain barrier. J. Pharm. Sci.89(11), 1371–1388 (2000).
  • Tsuji A , TamaiI. Carrier-mediated or specialized transport of drugs across the blood–brain barrier. Adv. Drug Deliv. Rev.36(2–3), 277–290 (1999).
  • Miller DS . Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. Trends Pharmacol. Sci.31(6), 246–254 (2010).
  • Allen DD , LockmanRP. The blood–brain barrier choline transporter as a brain drug delivery vector. Life Sci.73(13), 1609–1615 (2003).
  • Kusuhara , H, Sugiyama Y, Active efflux across the blood–brain barrier: role of the solute carrier family. NeuroRx2(1), 73–85 (2005).
  • Smith QR , StollJ. Blood–brain barrier amino acid transport. In: Introduction to Blood–Brain Barrier. Pardridge MW (Ed.). Cambridge University Press, Cambridge, UK (1998).
  • Saheki A , TerasakiT, TamaiI, TsujiA. In vivo and in vitro blood–brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res.11(2), 305–311 (1994).
  • Tsuji A , SahekiA, TamaiI, TerasakiT. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood–brain barrier. J. Pharmacol. Exp. Ther.267(3), 1085–1090 (1993).
  • Adkison KD , ShenDD. Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J. Pharmacol. Exp. Ther.276(3), 1189–1200 (1996).
  • Alam MI , BegS, SamadAet al. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 40(5), 385–403 (2010).
  • Girardin F . Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci.8(3), 311–321 (2006).
  • Uchino H , KanaiY, KimDKet al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharmacol. 61(4), 729–737 (2002).
  • Takada Y , VisticaDT, GreigNH, PurdonD, RapoportSI, SmithQR. Rapid high-affinity transport of a chemotherapeutic amino acid across the blood–brain barrier. Cancer Res.52(8), 2191–2196 (1992).
  • Matharu J , OkiJ, WorthenDR, SmithQR, CrooksPA. Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood–brain barrier. Bioorg. Med. Chem. Lett.20(12), 3688–3691 (2010).
  • Sekine T Cha HS, and Endou H, The multispecific organic anion transporter (OAT) family. Pflugers Arch.440(3), 337–350 (2000).
  • Ahn SY , EralySA, TsigelnyI, NigamSK. Interaction of organic cations with organic anion transporters. J. Biol. Chem.284(45), 31422–31430 (2009).
  • Tamai I , NozawaT, KoshidaM, NezuJ, SaiY, TsujiA. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res.18(9), 1262–1269 (2001).
  • Tamai I , NezuJ, UchinoHet al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273(1), 251–260 (2000).
  • Schmitt BM , GorbunovD, SchlachtbauerP. Charge-to-substrate ratio during organic cation uptake by rat OCT2 is voltage dependent and altered by exchange of glutamate 448 with glutamine. Am. J. Physiol. Renal Physiol.296(4), F709–F722 (2009).
  • Koepsell H Schmitt MB, Gorboulev V. Organic cation transporters. Rev. Physiol. Biochem. Pharmacol.150, 36–90 (2003).
  • Moaddel R , RavichandranS, BighiF, YamaguchiR, WainerIW. Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Br. J. Pharmacol.151(8), 1305–1314 (2007).
  • Yamazaki M , TerasakiT, YoshiokaKet al. Carrier-mediated transport of H1-antagonist at the blood–brain barrier: a common transport system of H1-antagonists and lipophilic basic drugs. Pharm. Res. 11(11), 1516–1518 (1994).
  • Yamazaki M , TerasakiT, YoshiokaKet al. Carrier-mediated transport of H1-antagonist at the blood–brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primary monolayer cultures. Pharm. Res. 11(7), 975–978 (1994).
  • Lockman PR , AllenDD. The transport of choline. Drug Dev. Ind. Pharm.28(7), 749–771 (2002).
  • Allen DD , SmithRQ. Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem.76(4), 1032–1041 (2001).
  • Allen DD , SmithRQ. Blood–brain barrier choline transport in the senescent rat. Neurosci. Lett.277(3), 198–202 (1999).
  • Klein J , KöppenA, LöffelholzK, SchmitthennerJ. Uptake and metabolism of choline by rat brain after acute choline administration. J. Neurochem.58(3), 870–876 (1992).
  • Smith QR , TakasatoY, SweeneyDJ, RapoportSI. Regional cerebrovascular transport of leucine as measured by the in situ brain perfusion technique. J. Cereb. Blood Flow Metab.5(2), 300–311 (1985).
  • Smith QR , TakasatoY, RapoportIS. Kinetic analysis of L-leucine transport across the blood–brain barrier. Brain Res.311(1), 167–170 (1984).
  • Takasato Y , RapoportIS, SmithRQ. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol.247(3 Pt2), H484–H493 (1984).
  • Lockman PR , RoderEK, AllenDD. Inhibition of the rat blood–brain barrier choline transporter by manganese chloride. J. Neurochem.79(3), 588–594 (2001).
  • Dwoskin LP , WootersTE, SumithranSP et al. N,N´-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J. Pharmacol. Exp. Ther.326(2), 563–576 (2008).
  • Zhang Z , LockmanPR, MittapalliRK, AllenDD, DwoskinLP, CrooksPA. bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett.18(20), 5622–5625 (2008).
  • Geldenhuys WJ , LockmanPR, NguyenTHet al. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood–brain barrier choline transporter. Bioorg. Med. Chem. 13(13), 4253–4261 (2005).
  • Geldenhuys WJ , MandaVK, MittapalliRKet al. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(3), 870–877 (2010).
  • Lockman PR , MandaPK, GeldenhuysWJet al. Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist N,N‘-dodecylbispicolinium dibromide at the blood–brain barrier. J. Pharmacol. Exp. Ther. 324(1), 244–250 (2008).
  • Zheng G , ZhangZ, LockmanPR et al. Bis-azaaromatic quaternary ammonium salts as ligands for the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett.20(11), 3208–3210 (2010).
  • Deuther-Conrad W , PattJT, LockmanPRet al. Norchloro-fluoro-homoepibatidine (NCFHEB) – a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur. Neuropsychopharmacol. 18(3), 222–229 (2008).
  • Allen DD , GeldenhuysWJ. Molecular modeling of blood–brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci.78(10), 1029–1033 (2006).
  • Debatin KM , PoncetD, KroemerG. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene21(57), 8786–8803 (2002).
  • Chang C Ray A, Swaan P. In silico strategies for modeling membrane transporter function. Drug Discov. Today10(9), 663–671 (2005).
  • Geldenhuys WJ , AllenDD, LockmanRP. 3-D-QSAR and docking studies on the neuronal choline transporter. Bioorg. Med. Chem. Lett.20(16), 4870–4877 (2010).
  • Allen DD , LockmanPR, RoderKE, DwoskinLP, CrooksPA. Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood–brain barrier choline transporter. J. Pharmacol. Exp. Ther.304(3), 1268–1274 (2003).
  • Geldenhuys WJ , LockmanPR, McAfeeJH, FitzpatrickKT, Van der Schyf CJ, Allen DD. Molecular modeling studies on the active binding site of the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett.14(12), 3085–3092 (2004).
  • Geldenhuys WJ , MandaVK, MittapalliRKet al. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood–brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(3), 870–877 (2010).
  • Salas-Burgos A , IserovichP, ZunigaF, VeraJC, FischbargJ. Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys. J.87(5), 2990–2999 (2004).
  • Bednarczyk D , EkinsS, WikelJH, WrightSH. Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol. Pharmacol.63(3), 489–498 (2003).
  • Mehdipour AR , HamidiM. Brain drug targeting: a computational approach for overcoming blood–brain barrier. Drug Discov. Today14(21–22), 1030–1036 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.